Clinical Trial Update: CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating avelumab plus cetuximab as a rechallenge strategy for metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Avelumab (avelumab)
• Cetuximab (cetuximab)

Snippet

Sponsor: University of Campania Luigi Vanvitelli | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: UNKNOWN